Sodium phenylbutyrate/ursodoxicoltaurine

Amylyx Pharmaceuticals Sued for Securities Law Violations; Investors Should Contact Block & Leviton for More Information

Retrieved on: 
tisdag, april 2, 2024
Amylyx Pharmaceuticals, Patient, Certification, Block & Leviton, ALS, Sodium phenylbutyrate/ursodoxicoltaurine

BOSTON, April 01, 2024 (GLOBE NEWSWIRE) -- A class action lawsuit has been filed against Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) for securities law violations.

Key Points: 
  • BOSTON, April 01, 2024 (GLOBE NEWSWIRE) -- A class action lawsuit has been filed against Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) for securities law violations.
  • Investors who purchased shares and have lost money are encouraged to contact the firm to learn more about how they might recover those losses.
  • Investors should contact Block & Leviton to learn more.
  • Block & Leviton is widely regarded as one of the leading securities class action firms in the country.

How Do Companies Avert Further Frustration among Neurologists Due to Relyvrio’s (Amylyx) Phase 3 Failure and Donanemab’s (Lilly) FDA delay?

Retrieved on: 
tisdag, mars 12, 2024
Diagnosis, Lecanemab, Alzheimer's disease, ALS, Sodium phenylbutyrate/ursodoxicoltaurine, Caregiver, Patient, Amyotrophy, News, Hope, Life, Life expectancy, Lilly, FDA, Donanemab, Pharmaceutical industry

ALS strikes adults in the prime of their life, is fatal, and the life expectancy of patients is generally 15 years or less.

Key Points: 
  • ALS strikes adults in the prime of their life, is fatal, and the life expectancy of patients is generally 15 years or less.
  • ALS patients maintain their cognitive functions while their muscle function deteriorates and eventually renders them bed-ridden, unable to swallow, and unable to breathe.
  • In an unusual decision the FDA conditionally approved Relyvrio based on the Phase 2 results as long as Phase 3 trial outcomes confirmed the results.
  • Only 40% of neurologists were initially aware of the FDA announcement regarding donanemab for Alzheimer's Disease (AD) when prompted.

Amylyx Pharmaceuticals Sued for Securities Law Violations; Investors Should Contact Block & Leviton for More Information

Retrieved on: 
fredag, mars 8, 2024
Amylyx Pharmaceuticals, Block & Leviton, Sodium phenylbutyrate/ursodoxicoltaurine, Certification, ALS, Patient, Cryptocurrency

BOSTON, March 08, 2024 (GLOBE NEWSWIRE) -- A class action lawsuit has been filed against Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) for securities law violations.

Key Points: 
  • BOSTON, March 08, 2024 (GLOBE NEWSWIRE) -- A class action lawsuit has been filed against Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) for securities law violations.
  • Investors who purchased shares and have lost money are encouraged to contact the firm to learn more about how they might recover those losses.
  • Investors should contact Block & Leviton to learn more.
  • Block & Leviton is widely regarded as one of the leading securities class action firms in the country.

AMYLYX INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Amylyx To Contact Him Directly To Discuss Their Options

Retrieved on: 
torsdag, februari 15, 2024
Court, BBC World Service, ALS, Sodium phenylbutyrate/ursodoxicoltaurine, News, Advertising, Investor's Business Daily, Q3, Woman, Patient, Amylyx Pharmaceuticals, LLP, ISI

NEW YORK, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Amylyx Pharmaceuticals, Inc. (“Amylyx” or the “Company”) (NASDAQ: AMLX) and reminds investors of the April 9, 2024 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

Key Points: 
  • If you suffered losses exceeding $100,000 investing in Amylyx stock or options between November 11, 2022 and November 8, 2023 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext.
  • Faruqi & Faruqi is a leading minority and Woman-owned national securities law firm with offices in New York, Pennsylvania, California and Georgia.
  • The same day, Investor's Business Daily published an article entitled "Amylyx Crashes 27% As New ALS Drug Faces A Barrage Of Troubles".
  • Faruqi & Faruqi, LLP also encourages anyone with information regarding Amylyx’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

Amylyx Pharmaceuticals Sued for Securities Law Violations; Investors Should Contact Block & Leviton for More Information

Retrieved on: 
måndag, februari 12, 2024
Amylyx Pharmaceuticals, Block & Leviton, Sodium phenylbutyrate/ursodoxicoltaurine, Certification, ALS, Patient

BOSTON, Feb. 12, 2024 (GLOBE NEWSWIRE) -- A class action lawsuit has been filed against Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) for securities law violations.

Key Points: 
  • BOSTON, Feb. 12, 2024 (GLOBE NEWSWIRE) -- A class action lawsuit has been filed against Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) for securities law violations.
  • Investors who purchased shares and have lost money are encouraged to contact the firm to learn more about how they might recover those losses.
  • Investors should contact Block & Leviton to learn more.
  • Block & Leviton is widely regarded as one of the leading securities class action firms in the country.

ALS Association Greater Philadelphia Chapter is Now ALS United Mid-Atlantic

Retrieved on: 
tisdag, februari 6, 2024
ALS Association, Growth, Knowledge, Celebration, Sodium phenylbutyrate/ursodoxicoltaurine, Research, MD, Nursing, FDA, Food, Disease, Delaware Valley, Health, Social, Doctor of Philosophy, Innovation, ALS

AMBLER, Pa., Feb. 6, 2024 /PRNewswire/ -- The ALS Association Greater Philadelphia Chapter has completed rebranding to become ALS United Mid-Atlantic.

Key Points: 
  • AMBLER, Pa., Feb. 6, 2024 /PRNewswire/ -- The ALS Association Greater Philadelphia Chapter has completed rebranding to become ALS United Mid-Atlantic.
  • This transition comes after the Greater Philadelphia Chapter joined 14 other Chapters in legally separating from The ALS Association on September 1, 2023.
  • These chapters represent approximately half of the ALS patient population and Certified Treatment Centers and ALS Clinics in the nation.
  • Videos highlighting these awards, ALS United Mid-Atlantic Treatment Centers, and a Call to Action to support the ALS Mission are available at https://www.youtube.com/@ALSMidAtlantic
    Over half of the budget of ALS United Mid-Atlantic is devoted to direct patient care.

AMYLYX ALERT: Bragar Eagel & Squire, P.C. is Investigating Amylyx Pharmaceuticals, Inc. on Behalf of Amylyx Stockholders and Encourages Investors to Contact the Firm

Retrieved on: 
söndag, januari 7, 2024
Telephone, Amylyx Pharmaceuticals, ISI, Patient, ALS, P.C, Sodium phenylbutyrate/ursodoxicoltaurine, News

NEW YORK, Jan. 06, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Amylyx Pharmaceuticals, Inc. (“Amylyx” or the “Company”) (NASDAQ: AMLX) on behalf of Amylyx stockholders.

Key Points: 
  • NEW YORK, Jan. 06, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Amylyx Pharmaceuticals, Inc. (“Amylyx” or the “Company”) (NASDAQ: AMLX) on behalf of Amylyx stockholders.
  • Our investigation concerns whether Amylyx has violated the federal securities laws and/or engaged in other unlawful business practices.
  • On November 9, 2023, Amylyx issued a press release announcing its third quarter (“Q3”) 2023 results, including Q3 GAAP earnings-per-share of $0.30, missing consensus estimates by $0.12.
  • The same day, Investor’s Business Daily published an article entitled “Amylyx Crashes 27% As New ALS Drug Faces A Barrage Of Troubles”.

Kirby McInerney LLP Continues Investigation of Shareholder Claims Against Amylyx Pharmaceuticals, Inc. (AMLX)

Retrieved on: 
torsdag, januari 4, 2024
Amylyx Pharmaceuticals, ISI, Patient, ALS, GAAP, Sodium phenylbutyrate/ursodoxicoltaurine, News, Private investigator

NEW YORK, Jan. 04, 2024 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP is investigating potential claims against Amylyx Pharmaceuticals, Inc. (“Amylyx” or the “Company”) (NASDAQ: AMLX ).

Key Points: 
  • NEW YORK, Jan. 04, 2024 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP is investigating potential claims against Amylyx Pharmaceuticals, Inc. (“Amylyx” or the “Company”) (NASDAQ: AMLX ).
  • The investigation concerns whether Amylyx and/or certain of its officers have violated the federal securities laws and/or engaged in other unlawful business practices.
  • On November 9, 2023, Amylyx issued a press release announcing its third quarter of 2023 results, including third quarter GAAP earnings-per-share of $0.30, missing consensus estimates by $0.12.
  • Kirby McInerney LLP is a New York-based plaintiffs’ law firm concentrating in securities, antitrust, whistleblower, and consumer litigation.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Amylyx Pharmaceuticals, Inc. - AMLX

Retrieved on: 
torsdag, december 14, 2023
ISI, ALS, LLP, News, Pomerantz, Sodium phenylbutyrate/ursodoxicoltaurine, Patient

NEW YORK, Dec. 14, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Amylyx Pharmaceuticals, Inc. (“Amylyx” or the “Company”) (NASDAQ: AMLX).

Key Points: 
  • NEW YORK, Dec. 14, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Amylyx Pharmaceuticals, Inc. (“Amylyx” or the “Company”) (NASDAQ: AMLX).
  • 7980
    The investigation concerns whether Amylyx and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
  • On November 9, 2023, Amylyx issued a press release announcing its third quarter (“Q3”) 2023 results, including Q3 GAAP earnings-per-share of $0.30, missing consensus estimates by $0.12.
  • The same day, Investor’s Business Daily published an article entitled “Amylyx Crashes 27% As New ALS Drug Faces A Barrage Of Troubles”.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Amylyx Pharmaceuticals, Inc. - AMLX

Retrieved on: 
måndag, december 4, 2023
ISI, ALS, LLP, News, Pomerantz, Sodium phenylbutyrate/ursodoxicoltaurine, Patient

NEW YORK, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Amylyx Pharmaceuticals, Inc. (“Amylyx” or the “Company”) (NASDAQ: AMLX).

Key Points: 
  • NEW YORK, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Amylyx Pharmaceuticals, Inc. (“Amylyx” or the “Company”) (NASDAQ: AMLX).
  • The investigation concerns whether Amylyx and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
  • The same day, Investor’s Business Daily published an article entitled “Amylyx Crashes 27% As New ALS Drug Faces A Barrage Of Troubles”.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.